Published in Gene Therapy Weekly, June 29th, 1998
This study examines the effects of G3139 in the treatment of Stage III and IV metastatic malignant melanoma in combination with dacarbazine (DTIC), a commonly used chemotherapy drug. The principal investigators in this study, Dr. Burkhard Jansen and Dr. Hubert Pehamberger, were also the key investigators in a preclinical study of the same combination in an animal model of human melanoma.
The clinical trial is designed to examine the effectiveness of the same combination in about thirty patients by measuring...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.